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Plasma Desmosine and Abdominal Aortic Aneurysm Disease
Ify R. Mordi, MD; Rachael O. Forsythe, PhD; Corry Gellatly, PhD; Zaid Iskandar, MBChB; Olivia M. McBride, MD; Athanasios Saratzis, PhD;
Rod Chalmers, MD; Calvin Chin, MD; Matthew J. Bown, MD; David E. Newby, PhD; Chim C. Lang, MD; Jeffrey T. J. Huang, PhD;
Anna-Maria Choy, MD
Background-—It is recognized that factors beyond aortic size are important in predicting outcome in abdominal aortic aneurysm
(AAA) disease. AAA is characterized by the breakdown of elastin within the aortic tunica media, leading to aortic dilatation and
rupture. The aim of this study was to investigate the association of plasma desmosine (pDES), an elastin-speciﬁc degradation
product, with disease severity and clinical outcome in patients with AAA.
Methods and Results-—We measured pDES and serum biomarker concentrations in 507 patients with AAAs (94% men; mean age,
72.46.1 years; mean AAA diameter, 488 mm) and 162 control subjects (100% men; mean age, 71.54.4 years) from 2
observational cohort studies. In the longitudinal cohort study (n=239), we explored the incremental prognostic value of pDES on AAA
events. pDES was higher in patients with AAA compared with control subjects (meanSD: 0.460.22 versus 0.330.16 ng/mL;
P<0.001) and had the strongest correlation with AAA diameter (r=0.39; P<0.0001) of any serum biomarker. After adjustment for
baseline AAA diameter, pDES was associated with an AAA event (hazard ratio, 2.03 per SD increase [95% CI, 1.02–4.02]; P=0.044). In
addition to AAA diameter, pDES provided incremental improvement in risk stratiﬁcation (continuous net reclassiﬁcation improvement,
34.4% [95% CI, 10.8% to 57.5%; P=0.09]; integrated discrimination improvement, 0.04 [95% CI, 0.00–0.15; P=0.050]).
Conclusions-—pDES concentrations predict disease severity and clinical outcomes in patients with AAA.
Clinical Trial Registration-—http://www.isrctn.com. Unique identiﬁer: ISRCTN76413758. ( J Am Heart Assoc.2019;8:e013743.
DOI: 10.1161/JAHA.119.013743.)
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A bdominal aortic aneurysm (AAA) is a common life-threatening disease that affects 1% to 2% of men by the
age of 65 years.1 The most worrying complication of AAA is
rupture, which is usually fatal, with a reported age-adjusted
annual mortality of 15.1 per 1 million people in the United
States.2,3 Randomized clinical trials of population screening in
men have demonstrated cost-effective reduction of AAA-
related mortality by 40% and have provided the underpin-
ning evidence for screening and surveillance programs for
men aged at least 65 years with surgical referral when AAA
diameter >5.5 cm.4,5 Strategies of repair of smaller aneur-
ysms have shown no beneﬁt, although there continues to be a
considerable risk of rupture, especially in women.6,7 Con-
versely, the rupture rate of AAAs above the 5.5-cm threshold
in the contemporary era is much lower than historically
reported; and many large AAAs do not rupture at all.8
Furthermore, there is an increasing appreciation that growth
of AAA is nonlinear,9 and the risk of rupture is time varying.
There is increasing recognition of the need to improve risk
stratiﬁcation in patients with AAA beyond measurement of the
aortic diameter.10,11 Biomarkers, especially those related to
pathophysiological processes of inﬂammation and aortic wall
degradation, are attractive potential candidates.10,12 How-
ever, no biomarker has yet been shown to provide enough
additional prognostic value to AAA diameter to enter into
routine clinical use.13,14 A key pathophysiological process is
loss of integrity of the extracellular matrix in the tunica media
of the aortic wall, resulting from elastin breakdown.15–19 A
recent review of biomarkers for prediction of AAA events
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suggested that serum elastin peptides, which are released in
the circulation when there is breakdown of elastin-rich tissue,
could hold promise for prediction of events in patients with
AAA; however, the authors agreed that larger prospective
studies are needed.20 Studies evaluating serum elastin
peptides have, however, been limited.21–23
Desmosine is a structural cross-linking amino acid that is
speciﬁcally released into the circulation when mature elastin
is broken down.24 We, therefore, hypothesized that plasma
desmosine (pDES) concentrations may reﬂect disease activity
in the aneurysm and could be used as a risk marker for AAA
events. The aim of this study was, therefore, to determine the
association of pDES concentrations with disease severity and
determine if pDES provides incremental prognostic value for
AAA-related clinical outcomes.
Methods
The data that support the ﬁndings of this study are available
from the corresponding authors on reasonable request.
Patient Populations
This study was conducted using analysis from 2 independent
study cohorts: the MA3RS (Magnetic Resonance Imaging for
Abdominal Aortic Aneurysms to Predict Rupture or Surgery)
study25 and the UKAGS (UK Aneurysm Growth Study).26 Full
details of the MA3RS study design have been described
previously.27 In brief, the MA3RS study was a prospective,
observational, multicenter cohort study of 342 patients with
AAA designed to determine the relationship between mural
ultrasmall superparamagnetic particles of iron oxide uptake
and clinical outcomes. Patients with AAA diameter >40 mm
were recruited from 3 Scottish centers between 2012 and
2014. In the MA3RS study, baseline assessment, including
computed tomography of the aorta and blood sampling, was
performed within 6 weeks of the screening abdominal
ultrasound. UKAGS is an ongoing, prospective, observational
cohort study of patients with small AAA (<55 mm) identiﬁed
from the National Health Service AAA screening programs in
England and Wales. UKAGS is currently in a recruitment phase
with ongoing longer-term follow-up. Details of the study have
been published previously.28 Screening participants from
UKAGS provided both patients with AAA as well as controls
(aortic diameter <30 mm). Baseline assessment, including
blood sampling, was performed at the time of the screening
abdominal ultrasound. For the purposes of this study, patients
were randomly selected from the UKAGS cohort to reﬂect the
range of aortic diameter. Both studies were approved by their
institutional review boards, and ethical approvals have been
previously sought for both the MA3RS study (East of Scotland
Research Ethics Service [12/ES/0068]) and UKAGS,29 with
consent for further research studies.
Participant Characterization
In all participants, abdominal aortic diameter was deﬁned as
the maximal anteroposterior inner wall to inner wall diameter
of the infrarenal aorta. Plasma samples from the MA3RS study
cohort and the selected cohort from the UKAGS were
analyzed for desmosine. pDES concentrations were analyzed
using a validated stable isotope dilution liquid chromatogra-
phy–tandem mass spectrometry method, as described previ-
ously.30 The lower limit of quantiﬁcation is 0.1 ng/mL. Other
biomarkers of interest (interleukin-6, matrix metallopro-
teinase-2, matrix metalloproteinase-9, and tissue inhibitor of
metalloproteinase-1) were obtained at baseline in the MA3RS
study, as described previously.27
Clinical Outcomes
Outcome data were available for the MA3RS study cohort.
Patients underwent 6 monthly assessments and were
followed up for at least 2 years for AAA events (AAA-related
death, rupture, or urgent repair). No outcome data are
available from the UKAGS as recruitment is ongoing and
completion of follow-up is not anticipated for some time.
Statistical Analysis
Continuous variables are reported as meanSD or median with
interquartile range, whereas categorical variables are reported
as number and percentage. As pDES concentrations were not
normally distributed, they were log transformed for analysis of
outcomes. Differences between groups were assessed using
Clinical Perspective
What Is New?
• Desmosine is a structural cross-link found in plasma after
breakdown of mature elastin.
• Plasma desmosine levels were signiﬁcantly higher in
patients with abdominal aortic aneurysms and were strongly
correlated with aortic diameter.
• Plasma desmosine levels were signiﬁcantly associated with
abdominal aortic aneurysm events after adjustment for
abdominal aortic aneurysm diameter.
What Are the Clinical Implications?
• Plasma desmosine may have potential as an additional
marker for assessing the risk of rupture in patients with
abdominal aortic aneurysms.
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unpaired t tests, analysis of variance, Kruskal-Wallis tests, or v2
tests, as appropriate. Correlations were assessed using Spear-
man’s correlation and linear regression. Association between
the earliest available pDES and clinical outcomes was assessed
using Cox regression (hazard ratio per SD change in log pDES)
and Kaplan-Meier analysis. Because of the limited number of
events and to prevent statistical overﬁtting, our multivariable
model only included variables associated with AAA events at
P<0.05 in univariable analysis. The optimal cutoff for pDES was
obtained using the Youden index (sensitivity+speciﬁcity-1). The
incremental predictive value of pDES in addition to AAA
diameter was determined using the C-statistic, net reclassiﬁ-
cation improvement, and integrated discrimination improve-
ment. All tests were 2 sided, and a P<0.05 was considered
signiﬁcant. All statistical analysis was performed using R 3.4.3
(Foundation for Statistical Computing, Vienna, Austria).
Results
Participant Characteristics
In total plasma, desmosine concentrations were available
from 669 individuals (507 patients with AAA and 162 controls
without AAA). Baseline characteristics of both patients with
AAA and controls are shown in Table 1. Overall, the cohort
was typical of patients with AAA (94% men; mean age,
72.46.1 years). Patients with AAA were more likely to be
smokers, have cardiovascular risk factors (diabetes mellitus,
hypertension, and hypercholesterolemia), and have had a
prior myocardial infarction.
Baseline characteristics of the MA3RS study cohort have
been reported previously.27 From the MA3RS study cohort,
560 plasma samples were collected from 239 patients at
different time points with contemporaneous abdominal ultra-
sound scans. Mean baseline AAA diameter in the index
MA3RS study cohort was 519 mm. Most patients were men,
and there was a high proportion of patients with cardiovas-
cular risk factors. Mean pDES in the MA3RS study cohort was
0.520.23 ng/mL.
In the UKAGS cohort, plasma samples were available from
430 participants, including 268 patients with AAA and 162
controls without AAA. Patients with AAA in UKAGS were of a
similar age to those in the MA3RS study and had a similar body
mass index, although there was a lower prevalence of
hypertension, smoking, hypercholesterolemia, and prior
myocardial infarction. There was a higher prevalence of
diabetes mellitus in UKAGS patients with AAA compared with
MA3RS study patients. Mean AAA diameter in UKAGSwas lower
than in the MA3RS study (438 versus 519 mm; P<0.001).
Mean aortic diameter in the control group was 205 mm.
pDES and Disease Severity
Overall, pDES levels in AAA patients was higher than controls
(AAA patients, 0.460.22 ng/mL; controls, 0.330.16 ng/
mL; P<0.001) (Figure 1).
pDES concentrations correlated with the maximal AAA
diameter, measured by ultrasound in both study cohorts
(MA3RS study cohort, r=0.26, P<0.001; UKAGS cohort,
r=0.15, P=0.002). This relationship was also seen in using
Table 1. Baseline Characteristics of the MA3RS Study and UKAGS Cohorts
Characteristics
All Patients With
AAA (n=507)
MA3RS Patients With
AAA (n=239)
UKAGS Patients With
AAA (n=268) Controls (n=162)
P Value Between AAA
Patients and Controls
Age, y* 72.46.1 73.17.1 71.75.0 71.54.4 0.044†
Men 477 (94.0) 209 (87.4) 268 (100) 162 (100) <0.001†
Body mass index, kg/m2* 27.74.3 27.34.1 28.24.7 27.23.6 0.58
Current smoker 107 (21.1) 66 (27.6) 41 (15.3) 9 (0.1) <0.001†
COPD 69 (13.6) 22 (9.2) 47 (17.5) 12 (7.4) <0.001†
Hypertension 323 (63.7) 172 (72.0) 151 (56.3) 75 (46.3) <0.001†
Type 2 diabetes mellitus 86 (17.0) 33 (13.8) 53 (19.8) 15 (9.3) 0.025†
Hypercholesterolemia 333 (65.7) 188 (78.7) 145 (54.1) 61 (37.7) <0.001†
Prior myocardial infarction 124 (24.5) 67 (28.0) 57 (21.2) 16 (9.9) <0.001†
Prior stroke 33 (6.5) 13 (5.4) 20 (7.5) 13 (8.0) 0.98
AAA ultrasound diameter, mm‡ 488 519 458 205 <0.001†
Data are given as meanSD or number (percentage). AAA indicates abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease; MA3RS, Magnetic Resonance Imaging Using
Ultrasound Superparamagnetic Particles of Iron Oxide to Predict Clinical Outcome in Patients Under Surveillance for Abdominal Aortic Aneurysms; UKAGS, UK Aneurysm Growth Study.
*Unpaired t test.
†p<0.05.
‡Kruskal-Wallis test.
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computed tomography assessment of the aorta within the
MA3RS study cohort (r=0.20; P=0.003). There was a stepwise
incremental increase in pDES concentrations, stratiﬁed by aortic
diameter, with those patients with large aneurysms having a
higher median pDES concentration than those with smaller
aneurysms (Figure 2). Across both cohorts, in multivariable
linear regression analysis, log pDES concentrations were
associated with AAA diameter after adjustment for age and
history of hypertension, smoking status, and chronic obstructive
pulmonary disease (COPD) (MA3RS study b, 3.36; SE, 1.34;
P=0.013; UKAGS b, 0.33; SE, 0.12; P=0.009) (Table 2).
pDES concentrations correlated with matrix metallopro-
teinase-2 (r=0.26; P<0.001), tissue inhibitor of metallopro-
teinase-1 (r=0.27; P<0.001), and interleukin-6 (r=0.30;
P<0.001) but not matrix metalloproteinase-9 (r=0.07;
P=0.31). However, pDES concentrations were more strongly
associated with aortic diameter than the other measured
biomarkers (interleukin-6, r=0.28, P=0.001; matrix metallo-
proteinase-2, r=0.14, P=0.053; matrix metalloproteinase-9,
r=0.01, P=0.90; tissue inhibitor of metalloproteinase-1,
r=0.16, P=0.027).
pDES and Disease Progression
From the MA3RS study cohort, 186 patients from the 239 had
>1 plasma sample available. There was no correlation
between change in pDES and change in AAA diameter at
the following visit (r=0.05; P=0.53). Patients with pDES higher
than the median did not have a signiﬁcantly higher AAA
diameter at 1 year than those with desmosine lower than the
median (pDES above median AAA increase, 2.56 versus
2.01 mm; P=0.15). In those patients with serial measure-
ments, desmosine levels were fairly stable, with patients
whose baseline desmosine level was below the median
remaining signiﬁcantly lower than those whose baseline
desmosine levels were higher over the 24-month follow-up
period (Figure 3).
pDES and Clinical Outcomes
In total, 13 (5.5%) of the 239 patients had an AAA event (11 AAA
deaths, 11 AAA ruptures, and 4 urgent repairs). Among baseline
clinical variables, AAA diameter was the only signiﬁcant
predictor of an AAA event (hazard ratio, 1.07 per mm increase;
95% CI, 1.03–1.12; P=0.002) (Table 3). In univariable analysis,
log pDES was associated with increased likelihood of an AAA
event (hazard ratio per SD increase, 2.43; 95% CI, 1.29–4.57;
P=0.006); and this remained the case after adjustment for AAA
Figure 1. Box plot of plasma desmosine (pDES) at baseline in the
MA3RS (Magnetic Resonance Imaging for Abdominal Aortic Aneur-
ysms to Predict Rupture or Surgery) study and UKAGS (UK Aneurysm
Growth Study) cohorts. Horizontal lines represent median plasma
desmosine, whereas diamonds represent mean plasma desmosine.
The mean plasma desmosine level for all patients with abdominal
aortic aneurysm (AAA) was 0.460.22 ng/mL; controls,
0.330.16 ng/mL (P<0.001, Kruskal-Wallis test).
Figure 2. Box plot of plasma desmosine (pDES) for all patients,
stratiﬁed by baseline abdominal aortic aneurysm diameter from
the MA3RS (Magnetic Resonance Imaging for Abdominal Aortic
Aneurysms to Predict Rupture or Surgery) study and UKAGS (UK
Aneurysm Growth Study) cohorts. Horizontal lines represent
median plasma desmosine, whereas diamonds represent mean
plasma desmosine. Mean plasma desmosine at ≥55 mm,
0.570.24 ng/mL; 35 to 54 mm, 0.470.22 ng/mL; and
<35 mm, 0.340.16 ng/mL (Kruskal-Wallis test).
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diameter (hazard ratio, 2.03 per SD increase; 95% CI, 1.02–
4.02; P=0.044) (Table 4). Similarly, after adjustment for both
AAA diameter and current smoking status (as smoking was the
variable most strongly associated with AAA diameter after
pDES), log pDES remained associated with the likelihood of
having an AAA event (hazard ratio per SD increase, 2.06; 95%
CI, 1.03–4.12; P=0.040). The optimal cutoff of pDES (deter-
mined using Youden’s index) for prediction of an AAA event was
0.56 ng/mL. Patients with pDES concentrations ≥0.56 ng/mL
weremore likely to have an AAA event (unadjusted hazard ratio,
6.77; 95% CI, 1.86–24.62; P=0.004; adjusted for AAA diameter
hazard ratio, 4.97; 95% CI, 1.31–18.90; P=0.019) (Figure 4).
pDES concentrations showed better discrimination for predic-
tion of an AAA event than other biomarkers (C-statistic: pDES,
0.70; interleukin-6, 0.49; matrix metalloproteinase-2, 0.52;
matrix metalloproteinase-9, 0.60; and tissue inhibitor of
metalloproteinase-1, 0.51).
The area under the curve for pDES for prediction of AAA
events was 0.70 (sensitivity, 0.77; speciﬁcity, 0.64; positive
predictive value, 0.11; negative predictive value, 0.98). When
combined with abdominal ultrasound AAA diameter, the
addition of pDES improved reclassiﬁcation for prediction of
AAA events (continuous net reclassiﬁcation improvement,
34.4%; 95% CI, 10.8% to 57.5%; P=0.09; integrated discrim-
ination improvement, 0.04; 95% CI, 0.00–0.15; P=0.05).
Discussion
This study is the largest study of a circulating biomarker in
AAA to date, and we have identiﬁed 3 novel ﬁndings. First,
pDES concentrations are higher in patients with AAA than in
control subjects, suggesting a potential role as a disease
marker. Second, it correlated with AAA diameter in 2
independent cohorts of patients. Third, it predicted clinical
Table 2. Multivariable Linear Regression for Association With
AAA Diameter in MA3RS Study and UKAGS
Study b Estimate SE P Value
MA3RS study
Age 0.19 0.09 0.023*
History of hypertension 1.56 1.24 0.21
History of diabetes mellitus 2.50 1.52 0.10
Current smoker 0.67 1.22 0.58
Chronic obstructive
pulmonary disease
2.87 1.85 0.12
Log plasma desmosine 3.36 1.34 0.013*
UKAGS
Age 0.01 0.01 0.48
History of hypertension 0.12 0.12 0.32
History of diabetes mellitus 0.23 0.17 0.17
Current smoker 0.83 0.19 <0.001*
Chronic obstructive
pulmonary disease
0.67 0.18 <0.001*
Log plasma desmosine 0.33 0.12 0.009*
AAA indicates abdominal aortic aneurysm; MA3RS, Magnetic Resonance Imaging Using
Ultrasound Superparamagnetic Particles of IronOxide to Predict Clinical Outcome in Patients
Under Surveillance for Abdominal Aortic Aneurysms; UKAGS, UK Aneurysm Growth Study.
*p<0.05.
Figure 3. Serial plot of mean plasma desmosine (pDES) over the 24-month follow-up period, stratiﬁed by
baseline desmosine. Points represent mean plasma desmosine in each group (stratiﬁed by baseline
desmosine levels). Error bars represent 95% CIs.
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outcome even after adjustment for AAA diameter, providing
incremental improvements in risk prediction. Finally, when
compared with other measured plasma biomarkers, pDES
demonstrated the strongest associations with aortic diameter
and prediction of AAA events. These ﬁndings suggest that
pDES may be a promising biomarker for prediction of adverse
clinical events in patients with AAA (Figure 5).
There has been intense interest in the utility of biomarkers to
monitor AAA size and their role in predicting rupture.13,14
However, none has been recommended for clinical use. A
recent systematic review of blood, imaging, and genetic
markers evaluated their prognostic value for the prediction of
AAA growth and rupture.20 Among them, serumelastin peptides
were the only plasma biomarker considered to have clinical
promise. Previous studies of serum elastin peptides in patients
with AAA have reported an association with AAA size and risk of
rupture21–23,31; however, the previously published studies have
been relatively small, with cohort sizes ranging from 100 to 150
patients, and 3 of the 4 studies of serum elastin peptides have
been from the same cohort of patients. Our study advances
these interesting exploratory results by using a single analyte,
pDES, as a speciﬁc marker of mature elastin breakdown, rather
than the more nonspeciﬁc serum elastin peptides. The results
of our study not only show a relationship between pDES and
AAA diameter, but also an association between baseline pDES
and AAA rupture, which is stronger than that reported with
serum elastin peptides,21,22 supporting our hypothesis that
pDES may be a more clinically useful biomarker. In our study,
other plasma biomarkers, such as MMP (matrix metallopepti-
dase)-9, were not signiﬁcantly associatedwith AAA diameter, as
has been found in several other studies, strengthening the case
for the potential utility of desmosine.20
Although intervention in patients with small aneurysms
(30–55 mm) has not been shown to be superior to surveil-
lance in randomized trials or meta-analyses,32 AAA ruptures
can still occur in patients who do not meet the criteria for AAA
repair, particularly in women who account for a third of deaths
caused by rupture; they remain at risk from cardiovascular
events.28,33 Given this, our ﬁnding that pDES was associated
with AAA events independent of aortic diameter suggests that
pDES may be useful as an additional risk marker, particularly
given the improvements in net reclassiﬁcation improvement
and integrated discrimination improvement. The independent
prognostic value of pDES suggests that it may be providing an
additional pathophysiological insight beyond AAA diameter.
In our study, there was interestingly no association
between pDES and AAA diameter progression, and this
contrasts with prior work using serum elastin peptides.31 The
reason for this discrepancy is unknown, although the
recognized nonlinear growth of aneurysmal progression may
partly account for this.9,34 We did see, however, that pDES
levels remained stable over time compared with baseline,
suggesting that single measurement of pDES at any time
point may be enough to provide a prediction of risk beyond
AAA diameter. We hypothesize that pDES is related to other
Table 3. Univariable Cox Regression Analysis for Association
With AAA Events
Variable Hazard Ratio (95% CI) P Value
Age (per year) 1.06 (0.98–1.15) 0.12
Female sex 1.26 (0.28–5.69) 0.76
Current smoker 1.82 (0.60–5.57) 0.29
History of hypertension 1.86 (0.41–8.39) 0.42
Diabetes mellitus 0.47 (0.06–3.61) 0.47
Hypercholesterolemia 2.89 (0.38–22.26) 0.31
History of angina 2.02 (0.55–7.33) 0.29
History of COPD 1.71 (0.38–7.71) 0.49
Previous myocardial infarction 0.69 (0.19–2.51) 0.57
Previous stroke 1.22 (0.16–9.41) 0.85
BMI (per kg/m2 increase) 0.99 (0.87–1.13) 0.89
Baseline systolic blood pressure
(per mm Hg increase)
1.00 (0.97–1.04) 0.82
AAA diameter (per mm increase) 1.07 (1.03–1.12) 0.002*
pDES (per SD increase) 2.43 (1.29–4.58) 0.006*
AAA indicates abdominal aortic aneurysm; BMI, body mass index; COPD, chronic
obstructive pulmonary disease; pDES, plasma desmosine.
*p<0.05.
Table 4. Cox Regression Analysis of Association of pDES With AAA Diameter
Variable No. of Events
Univariable Hazard Ratio
(95% CI) per SD Increase P Value
Hazard Ratio (95% CI) per SD
Increase Adjusted for AAA Diameter P Value
AAA event 13 2.43 (1.29–4.58) 0.006* 2.03 (1.02–4.02) 0.044*
AAA death 11 2.46 (1.23–4.91) 0.011* 1.97 (0.92–4.21) 0.08
AAA rupture 11 2.46 (1.23–4.91) 0.011* 1.97 (0.92–4.21) 0.08
Urgent repair 4 3.58 (1.03–12.45) 0.044* 2.73 (0.73–10.17) 0.13
AAA indicates abdominal aortic aneurysm; pDES, plasma desmosine.
*p<0.05.
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parameters of risk beyond AAA diameter, perhaps related to
vessel wall integrity.10 Using this assay speciﬁc for desmosine
rather than general serum elastin peptides, we have shown
the independent and incremental value of pDES in predicting
clinical events when added to AAA diameter, which has never
been demonstrated with previously studied biomarkers.35,36
Follow-up data in our study were also only available in the
MA3RS study cohort, in which patients had a larger AAA
diameter at baseline compared with those in the studies of
serum elastin peptides, which largely focused on patients with
smaller AAAs.21,22,37
Although pulmonary elastin breakdown is a component of
conditions such as COPD, a large study of 1177 stable patients
with COPD found that pDES was not a predictor of emphysema
progression or lung function decline but that pDES was
increased in those patients with COPD and underlying cardio-
vascular disease. A similar lack of association between pDES
and lung function decline was found in patients with bronchiec-
tasis.38 This suggests that pDES appears to be more speciﬁc to
vascular elastin breakdown as opposed to lung elastin and,
hence, could be useful in monitoring patients with AAA.28 In
addition, we have previously shown that smoking, although
associated with AAA diameter in our study, is not associated
with pDES levels.39 In our study, pDES was associated with
aortic diameter independent of COPD and smoking status.
The main limitations of this study were as follows. First,
although we have used 2 prospectively recruited cohorts of
reasonable size, we still have relatively few events in our
outcome MA3RS study cohort, limiting the ability to adjust for
other confounders. We were, however, able to adjust for AAA
diameter (which was the only other signiﬁcant predictor of
outcome in our study), and pDES remained predictive of adverse
outcome. In addition, both cohorts were obtained frommultiple
centers, increasing generalizability of the results. Although
assessment of AAA diameter using ultrasound does have
limitations on intraobserver and interobserver variability, it is
the main method used in clinical practice. In addition, we also
found a signiﬁcant correlation between pDES and computed
tomographic aorta diameter within the MA3RS study cohort.
Second, few women were included in our study, typical of
studies in patients with AAA. This is particularly important as
female sex is itself an important predictor of AAA rupture,40 and
a third of all deaths caused by AAA rupture are in women.41,42
This does, however, highlight a potential need for a biomarker,
as on the basis of size and high surgical risk, women are often
less likely to undergo AAA repair,43 and screening programs for
women based on aortic size, similar to that for men, do not
appear to be cost-effective.44 Finally, as recruitment to UKAGS
is ongoing, we do not have follow-up data in this group of
patients with smaller AAAs, and outcomes are not anticipated
Figure 4. Kaplan-Meier curve for emergency abdominal aortic aneurysm events based on the optimal
cutoff for plasma desmosine (log-rank P<0.001).
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to be imminently available. Given the relatively small number of
events, these results must be seen as preliminary, although
intriguing.
In conclusion, we have found that pDES concentrations are
increased in patients with AAA disease and correlate with
disease severity. pDES concentrations also appear to predict
adverse clinical outcomes, even after adjustment for AAA
diameter. pDES is a promising new marker of AAA risk that is
independent and incremental to AAA diameter. Larger studies
are warranted to validate optimal cutoff thresholds and allow
integration into clinical use.
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